Clinical

Dataset Information

0

Pharmacogenomic study on colorectal cancer chemotherapy - modified FOLFOX6- (Oxaliplatin with infusional 5-FU/l-Leucovorin) and FOLFIRI (irinotecan with infusional 5-FU/l-Leucovorin)-based regimen-


ABSTRACT: Interventions: mFOLFOX6 (-BEV): On Day1, iv infusion of 85 mg/m2 of l-OHP and 175 mg/m2 of L-LV for 2hrs, followed by bolus infusion of 400 mg/m2 5-FU. Then, continuous infusion of 2400 mg/m2 5-FU for 46 hrs. 1 course, 2 weeks. Continue the courses till the discontinuance criteria. mFOLFOX6 (+BEV): The first treatment after the surgery is subject to the mFOLFOX6 (-BEV) regimen. From the 2nd cycle, first infusion of 5 mg/kg BEV. Then follow the mFOLFOX6 (-BEV) regimen. 1 course, 2 weeks. Continue the courses till the discontinuance criteria. mFOLFIRI(-BEV): On Day1, iv infusion of 150 mg/m2 of CPT-11 and 175 mg/m2 of L-LV for 2 hrs, followed by bolus infusion of 400 mg/m2 5-FU. Then, continuous infusion of 2400 mg/m2 5-FU for 46 hrs. 1 course, 2 weeks. Continue the courses till the discontinuance criteria. mFOLFIRI (+BEV): The first treatment after the surgery is subject to the FOLFIRI (-BEV) regimen. From the 2nd cycle, first infusion of 5 mg/kg BEV. Then follow the FOLFIRI (-BEV) regimen. 1 course, 2 weeks. Continue the courses till the discontinuance criteria. Primary outcome(s): Response rate (RECISTv1.1) Study Design: Parallel Randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2622327 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2013-01-01 | GSE41998 | GEO
2009-04-01 | GSE12062 | GEO
| 2614012 | ecrin-mdr-crc
2013-01-01 | E-GEOD-41998 | biostudies-arrayexpress
| 2616231 | ecrin-mdr-crc
| 2623706 | ecrin-mdr-crc
| 2620921 | ecrin-mdr-crc
| 2609649 | ecrin-mdr-crc
| 2613819 | ecrin-mdr-crc
| 2620327 | ecrin-mdr-crc